184 related articles for article (PubMed ID: 1663586)
1. Endothelium-derived bradykinin is responsible for the increase in calcium produced by angiotensin-converting enzyme inhibitors in human endothelial cells.
Busse R; Lamontagne D
Naunyn Schmiedebergs Arch Pharmacol; 1991 Jul; 344(1):126-9. PubMed ID: 1663586
[TBL] [Abstract][Full Text] [Related]
2. Endothelium-derived bradykinin: implications for angiotensin-converting enzyme-inhibitor therapy.
Busse R; Fleming I; Hecker M
J Cardiovasc Pharmacol; 1993; 22 Suppl 5():S31-6. PubMed ID: 7508049
[TBL] [Abstract][Full Text] [Related]
3. Role of endothelium-derived bradykinin in the control of vascular tone.
Hecker M; Dambacher T; Busse R
J Cardiovasc Pharmacol; 1992; 20 Suppl 9():S55-61. PubMed ID: 1282631
[TBL] [Abstract][Full Text] [Related]
4. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin.
Wiemer G; Schölkens BA; Becker RH; Busse R
Hypertension; 1991 Oct; 18(4):558-63. PubMed ID: 1655653
[TBL] [Abstract][Full Text] [Related]
5. Stimulation of endothelial autacoid formation by inhibitors of angiotensin-converting enzyme.
Hecker M; Benzing T; Busse R
Agents Actions Suppl; 1992; 38 ( Pt 3)():163-70. PubMed ID: 1281378
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of cytosolic calcium, prostacyclin and nitric oxide by bradykinin and the ACE inhibitor ramiprilat in porcine brain capillary endothelial cells.
Wiemer G; Popp R; Schölkens BA; Gögelein H
Brain Res; 1994 Feb; 638(1-2):261-6. PubMed ID: 7515323
[TBL] [Abstract][Full Text] [Related]
7. Significance of endothelial prostacyclin and nitric oxide in peripheral and pulmonary circulation.
Gryglewski RJ; Chłopicki S; Uracz W; Marcinkiewicz E
Med Sci Monit; 2001; 7(1):1-16. PubMed ID: 11208485
[TBL] [Abstract][Full Text] [Related]
8. Converting enzyme inhibitor-stimulated formation of nitric oxide and prostacyclin in endothelial cells from bovine aorta is mediated by endothelium-derived bradykinin.
Wiemer G; Schölkens BA; Becker RH
Agents Actions Suppl; 1992; 38 ( Pt 3)():196-200. PubMed ID: 1334350
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin-converting enzyme inhibitors unmask endogenous kinin production by bovine coronary artery endothelium.
Hecker M; Bara AT; Busse R
Eur Heart J; 1993 Nov; 14 Suppl I():161-3. PubMed ID: 8293768
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of endothelium-dependent relaxations to bradykinin by angiotensin I converting enzyme inhibitors in canine coronary artery involves both endothelium-derived relaxing and hyperpolarizing factors.
Mombouli JV; Illiano S; Nagao T; Scott-Burden T; Vanhoutte PM
Circ Res; 1992 Jul; 71(1):137-44. PubMed ID: 1318793
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin-converting enzyme inhibitor ramiprilat interferes with the sequestration of the B2 kinin receptor within the plasma membrane of native endothelial cells.
Benzing T; Fleming I; Blaukat A; Müller-Esterl W; Busse R
Circulation; 1999 Apr; 99(15):2034-40. PubMed ID: 10209009
[TBL] [Abstract][Full Text] [Related]
12. Relaxation of isolated coronary arteries by angiotensin-converting enzyme inhibitors: role of endothelium-derived kinins.
Hecker M; Bara AT; Busse R
J Vasc Res; 1993; 30(5):257-62. PubMed ID: 8399986
[TBL] [Abstract][Full Text] [Related]
13. The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors.
Hartman JC
Ann Thorac Surg; 1995 Sep; 60(3):789-92. PubMed ID: 7545893
[TBL] [Abstract][Full Text] [Related]
14. Bradykinin inhibits serum-depletion-induced apoptosis of human vascular endothelial cells by inducing nitric oxide via calcium ion kinetics.
Kono Y; Sawada S; Kawahara T; Tsuda Y; Higaki T; Yamasaki S; Imamura H; Tada Y; Sato T; Hiranuma O; Akamatsu N; Komatsu S; Tamagaki T; Nakagawa K; Tsuji H; Nakagawa M
J Cardiovasc Pharmacol; 2002 Feb; 39(2):251-61. PubMed ID: 11791011
[TBL] [Abstract][Full Text] [Related]
15. Local regulation of vascular tone by bradykinin and angiotensin converting enzyme inhibitors.
Auch-Schwelk W; Kuchenbuch C; Claus M; Walther B; Bossaller C; Friedel N; Graf K; Gräfe M; Fleck E
Eur Heart J; 1993 Nov; 14 Suppl I():154-60. PubMed ID: 8293767
[TBL] [Abstract][Full Text] [Related]
16. Endothelial function and bradykinin in humans.
Hornig B; Drexler H
Drugs; 1997; 54 Suppl 5():42-7. PubMed ID: 9429844
[TBL] [Abstract][Full Text] [Related]
17. Potentiation by ACE inhibitors of the dilator response to bradykinin in the coronary microcirculation: interaction at the receptor level.
Hecker M; Pörsti I; Bara AT; Busse R
Br J Pharmacol; 1994 Jan; 111(1):238-44. PubMed ID: 8012702
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms involved in the angiotensin II-independent hypotensive action of ACE inhibitors.
Hecker M; Pörsti I; Busse R
Braz J Med Biol Res; 1994 Aug; 27(8):1917-21. PubMed ID: 7749381
[TBL] [Abstract][Full Text] [Related]
19. Role of bradykinin in the cardiac effects of angiotensin-converting enzyme inhibitors.
Linz W; Schölkens BA
J Cardiovasc Pharmacol; 1992; 20 Suppl 9():S83-90. PubMed ID: 1282635
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin.
Pretorius M; Rosenbaum D; Vaughan DE; Brown NJ
Circulation; 2003 Feb; 107(4):579-85. PubMed ID: 12566370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
